文献速递胸部肿瘤

奥希替尼致QT间期延长:新药新副作用需密切监测

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
PubMed 文献 · Eur J Cancer · 2018-01-01

本文以一名接受奥希替尼治疗的EGFR突变晚期NSCLC患者为例,该患者出现III级QT间期延长,停药后发生症状性疾病 flare 且对后续全身治疗无反应。文章旨在描述此类患者QT间期延长的管理,并讨论因停药导致疾病 flare 风险与心源性猝死风险之间的伦理权衡,同时汇总肺癌TKI治疗的监测建议和常见药物-TKI相互作用。

要点

  • 奥希替尼等TKI可致QT间期延长,高危患者应筛查。
  • 停药可能导致疾病 flare,需权衡心脏猝死与 flare 风险。
  • 家族猝死史和QT延长可能提示家族性长QT综合征。

核心结论

  • 奥希替尼治疗中可出现III级QT间期延长,停药后可能发生症状性疾病 flare 且对后续治疗无反应。
  • 临床需在高危患者中筛查QT间期延长,并权衡停药导致疾病 flare 与心源性猝死的风险。

研究设计与样本

  • 本文为视角类文章,报告一例接受奥希替尼治疗的EGFR突变晚期NSCLC患者出现III级QT间期延长。

主要发现

  • 患者停用奥希替尼后出现症状性疾病 flare,且对后续全身治疗无反应。
  • 家族猝死史和QT间期延长可能提示家族性长QT综合征。

关键数值与推荐

  • 对于奥希替尼、克唑替尼、色瑞替尼等TKI,建议在高风险患者中筛查QT间期延长。

临床怎么用

  • 对使用奥希替尼等TKI的肺癌患者,尤其高危者,应监测QT间期并注意药物-TKI相互作用。
  • 出现QT间期延长时,需个体化评估是否停药,综合考虑疾病 flare 与心源性猝死风险。

局限性

  • 本文为单例报告与视角讨论,未提供大规模研究数据或定量风险估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An increasing number of tyrosine kinase inhibitors (TKIs) are available for the treatment of non-small cell lung cancer (NSCLC). QT prolongation is one of the known, but relatively rare, adverse events of several TKIs (e.g. osimertinib, crizotinib, ceritinib). Screening for QT prolongation in (high risk) patients is advised for these TKIs. When a QT prolongation develops, the physician is challenged with the question whether to (permanently) discontinue the TKI. In this perspective, we report on a patient who developed a grade III QT prolongation during osimertinib (a third-generation epidermal growth factor receptor [EGFR]-TKI) treatment. On discontinuation of osimertinib, she developed a symptomatic disease flare, not responding to subsequent systemic treatment. The main aim of this perspective is to describe the management of QT prolongation in stage IV EGFR driver mutation NSCLC patients. We also discuss the ethical question of how to weigh the risk of a disease flare due to therapy cessation against the risk of sudden cardiac death. A family history of sudden death and a prolonged QT interval might indicate a familiar long QT syndrome. We have summarised the current monitoring advice for TKIs used in the treatment of lung cancer and the most common drug-TKI interactions to consider and to optimise TKI treatment in lung cancer patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schiefer M, Hendriks LEL, Dinh T, et al. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018. PMID: 29413968. doi:10.1016/j.ejca.2017.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。